spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Myriad Genetics 

 HSMN NewsFeed - 5 Dec 2022
Immunovia strengthens US organization to continue commercialization of its novel IMMray(TM) PanCan-d test
Diagnostics Oncology Personnel
 HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Apr 2019
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Jan 2019
Nanospectra Biosciences Names Michael Brawer, M.D. as Chief Medical Officer
Devices Oncology Urology Personnel
 HSMN NewsFeed - 15 Sep 2017
Myriad Genetics Announces Positive Data Supporting New riskScore(TM) Test at the 36th Annual Conference of the National Society of Genetic Counselors
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 7 Sep 2017
Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
Diagnostics Oncology
 HSMN NewsFeed - 18 Aug 2017
EndoPredict(R) Receives Positive Coverage Decisions From Medicare and Anthem
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 25 May 2017
Medicare Coverage of Prolaris(R) Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 13 Mar 2017
Myriad Genetics Launches the EndoPredict(R) Test in the United States for Patients with Breast Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 7 Nov 2016
Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx(R)
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 4 Nov 2016
The GeneSight(R) Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder
Diagnostics Personalized Medicine
 HSMN NewsFeed - 27 Oct 2016
The Myriad myPath(R) Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnostic
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 20 Oct 2016
Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
Diagnostics Oncology Personnel
 HSMN NewsFeed - 29 Sep 2016
Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
Diagnostics Personnel
 HSMN NewsFeed - 18 Mar 2016
The Myriad myRisk(R) Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 19 Jan 2016
Amylyx Announces Election of Nobel Laureate Walter Gilbert, PhD, to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Jan 2016
Counsyl Appoints Ted Snelgrove as Chief Business Officer
Diagnostics Personnel
 HSMN NewsFeed - 29 May 2015
Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting
Diagnostics Oncology
 HSMN NewsFeed - 8 Jan 2015
Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 2 Dec 2014
Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years
Diagnostics Urology Oncology
 HSMN NewsFeed - 19 Nov 2014
Crescendo Bioscience Highlights New Clinical Data on Vectra(R) DA at ACR
Diagnostics
 HSMN NewsFeed - 7 Nov 2014
Myriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 24 Oct 2014
Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe
Diagnostics Oncology
 HSMN NewsFeed - 9 Sep 2014
Myriad myPath(TM) Melanoma Test Reduced Indeterminate Cases by 76 Percent and Changed Treatment in 35 Percent of Cases
Diagnostics Oncology
 HSMN NewsFeed - 14 Aug 2014
Vermillion Announces Additions to Commercial Management Team
Diagnostics Personnel
 HSMN NewsFeed - 2 Jun 2014
Myriad myPath(TM) Melanoma Test Improves the Reliability of Melanoma Diagnosis
Diagnostics Dermatology Oncology
 HSMN NewsFeed - 2 Jun 2014
Myriad Presents Clinical Data on Myriad myRisk(TM) Hereditary Cancer Test at ASCO
Diagnostics Oncology
 HSMN NewsFeed - 6 May 2014
Myriad and UnitedHealthcare Sign Three-Year Agreement Making myRisk(TM) Hereditary Cancer Test Available to United Members
Diagnostics Oncology
 HSMN NewsFeed - 1 May 2014
Myriad to Launch EndoPredict(R) in Canada
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 3 Mar 2014
Myriad Publishes Clinical Utility Study for Prolaris(R)
Diagnostics Urology
 HSMN NewsFeed - 11 Feb 2014
Zocere Appoints Zavitz as Chief Scientific Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Feb 2014
BRCA Patent Owners and Gene by Gene, Ltd. Resolve Patent Suit
Diagnostics Oncology Litigation
 HSMN NewsFeed - 29 Jan 2014
Myriad's Prolaris(R) Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 12 Dec 2013
Myriad myRisk Hereditary Cancer(TM) Test Significantly Improves Detection of Women at Risk for Hereditary Cancer by 51 Percent
Diagnostics Oncology
 HSMN NewsFeed - 9 Dec 2013
Myriad Genetics Announces Cancer Research Collaboration With Janssen
Diagnostics Oncology
 HSMN NewsFeed - 4 Dec 2013
Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
Diagnostics Urology Oncology
 HSMN NewsFeed - 12 Nov 2013
Myriad Genetics Launches myPath(TM) Melanoma Diagnostic Test
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 Oct 2013
Myriad myPlan(TM) Lung Cancer Test Launched to Leading Oncologists
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 28 Oct 2013
Myriad myPlan(TM) Lung Cancer Test Meets Primary Endpoint in Validation Study
Diagnostics Oncology
 HSMN NewsFeed - 24 Oct 2013
Myriad myRisk(TM) Hereditary Cancer Test Is Highly Accurate in Key Validation Study
Diagnostics Oncology
 HSMN NewsFeed - 22 Oct 2013
BioReference Laboratories, Inc. Sued by Myriad Genetics, Confident in Its Position
Diagnostics Oncology Litigation
 HSMN NewsFeed - 14 Oct 2013
Myriad's myPath(TM) Melanoma Test is Highly Effective in Verification Study
Diagnostics Oncology Dermatology
 HSMN NewsFeed - 5 Sep 2013
Myriad Genetics Launches myRisk(TM) Hereditary Cancer Panel
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 13 Jun 2013
Supreme Court Upholds Myriad's cDNA Patent Claims
Diagnostics Oncology Litigation
 HSMN NewsFeed - 13 Jun 2013
GeneDx to Launch Comprehensive Breast Cancer Genetic Test
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 27 Mar 2013
AdvanDx, Inc. Elects Former Roche Molecular Systems CEO, Heiner Dreismann, Ph.D., to its Board of Directors
Diagnostics Personnel
 HSMN NewsFeed - 5 Mar 2013
Myriad's Prolaris(R) Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study
Diagnostics Urology Oncology
 HSMN NewsFeed - 5 Nov 2012
Amedica Names Distinguished Health Care Industry Executive Jay M. Moyes To Board Of Directors
Devices Orthopaedic Neurosurgery Personnel
 HSMN NewsFeed - 19 Sep 2012
Louise Phanstiel Joins Verastem Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Sep 2012
Genetic Technologies Announces Key Managerial Appointment
Diagnostics Personnel
 HSMN NewsFeed - 9 Dec 2011
Myriad Genetics Presents BRACAnalysis(R) Cost-Effectiveness Study at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Diagnostics Oncology
 HSMN NewsFeed - 2 May 2011
Saladax Biomedical, Inc. Announces European Commercialization Team
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 10 Mar 2011
Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 7 Jan 2011
BioCardia elects Industry Veteran, Jay M. Moyes, to Board of Directors
Devices Regenerative Medicine Cardiology Personnel
 HSMN NewsFeed - 20 Dec 2010
Myriad Genetics Launches PANEXIA, New Predictive Test for Hereditary Pancreatic and Related Cancers
Diagnostics Oncology
 HSMN NewsFeed - 8 Dec 2010
Myriad Acquires Novel Technology From Melanoma Diagnostics
Diagnostics Oncology Acquisitions
 HSMN NewsFeed - 26 Oct 2010
Myriad and Abbott Enter Into Cooperative Agreement
Diagnostics Oncology
 HSMN NewsFeed - 6 Jul 2010
EpiCept Corporation Names Rita Kelley Senior Director of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2010
EpiCept Corporation Announces Commercial Launch of Ceplene(R) in Germany
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2010
EpiCept Announces Commercial Launch of Ceplene(R) in the United Kingdom
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2010
Saladax Biomedical Closes $8 Million Series C Financing
Personalized Medicine Diagnostics Venture Capital
 HSMN NewsFeed - 2 Mar 2010
Myriad Genetics Launches PROLARIS(TM): First Diagnostic Test to Predict Prostate Cancer Recurrence
Diagnostics Oncology
 HSMN NewsFeed - 9 Feb 2010
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2010
EpiCept Receives Orphan Drug Designation for EpiCept NP-1 in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2010
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 6 Nov 2009
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2009
NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2009
GENova names Dr. John Savin as Vice President
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2009
Myriad Applauds New ACOG Guidelines for Hereditary Breast and Ovarian Cancer
Diagnostics Oncology
 HSMN NewsFeed - 21 Jan 2009
Myriad Pharmaceuticals Acquires Novel HIV Drug, Bevirimat
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology
 HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Sep 2008
EpiCept Amends DURECT Bupivacaine Patch Licensing Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 11 Sep 2008
Myriad Genetics Board Explores Prospect of Separating Diagnostic and Pharmaceutical Businesses
Biopharmaceuticals Diagnostics
 HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 12 Jun 2008
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 May 2008
Myriad Genetics Selects Lundbeck as European Partner for Flurizan
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Mar 2008
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Feb 2008
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2008
Myriad Genetics, Inc. Expands Commercial and Clinical Infrastructure
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2007
Myriad Genetics Submits IND on Vivecon
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Sep 2007
EpiCept Reports Regulatory Progress on Ceplene(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Sep 2007
Myriad Genetics Launches Awareness Advertising Campaign to Educate Women About Hereditary Risks of Breast and Ovarian Cancers
Diagnostics Oncology
 HSMN NewsFeed - 16 Aug 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2007
Myriad Genetics Launches New Molecular Diagnostic Test
Diagnostics Oncology
 HSMN NewsFeed - 19 Jun 2007
Myriad Genetics Collaborates With AstraZeneca on Phase 2 Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2007
Myriad Presents Additional Flurizan(TM) Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Feb 2007
Pipex Pharmaceuticals, Inc. Announces the Appointment of Daniel J. Dorman and James S. Kuo, M.D., M.B.A. to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
Myriad Genetics Announces Results of Phase 2 Prostate Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2006
Myriad Genetics Sponsors Clinical Trial in Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
QuantRx(R) Biomedical Appoints Former FDA Commissioner Dr. Arthur Hull Hayes, Jr. to Board of Directors
Diagnostics Personnel
 HSMN NewsFeed - 19 Jul 2006
Myriad's 24-Month Study of Flurizan Demonstrates Significant Benefit in Alzheimer's Disease Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Jul 2006
Lipocine Inc. Announces Strengthening of Its Senior Management Team With Addition of Robert Merrell as Vice President of Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 May 2006
MultiCell Technologies Appoints Stephen Chang, Ph.D. as Chief Executive Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 45

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 45 additional stories matching:
Myriad Genetics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.